AVDL (Avadel Pharmaceuticals PLC) רווח נקי למניה אחת בשנים עשר החודשים האחרונים

Risks for Avadel Pharmaceuticals (AVDL) are linked to the recognition of the drug Lumryz and patent disputes, which is confirmed by the annual EPS TTM growth measurement shown on this GURU.Markets chart, where the latest value is recorded as 99.40. Avadel Pharmaceuticals (AVDL) relies on outsourced production and logistics, while its human capital is based on highly specialized experts with a flexible bonus system.
Avadel Corp - פילוחים אנליטיים ומדדי מפתח (AVDL)

This indicator measures the rolling annual growth of earnings per share, neutralizing quarterly reporting gaps and filtering out short-term market noise to reveal the true trajectory of profitability. For Avadel Pharmaceuticals (AVDL), with its focus on costly R&D in microencapsulation, the current EPS YoY TTM growth trend serves as a marker for the efficiency of innovation commercialization and the accuracy of the business's fundamental valuation.